Search

Displaying results 2681 - 2690 of 10000 in total
  1. Drug

    Zoliflodacin

    go.drugbank.com/drugs/DB12817
    ApprovedInvestigational

    [A274938,L54748] It is indicated as a single-dose oral therapy for the treatment of uncomplicated urogenital gonorrhea.

  2. Drug

    mRNA-1283

    go.drugbank.com/drugs/DB22668
    ApprovedInvestigational

    2 spike protein, allowing for a more targeted immune response and the use of a significantly smaller amount of mRNA per dose. … mRNA-1283 is a nucleoside-modified messenger RNA (mRNA) encoding the N-terminal domain (NTD) and receptor-binding domain (RBD) of the spike glycoprotein of the SARS-CoV-2 Omicron variant lineage JN.1.

  3. Drug

    Sotrovimab

    go.drugbank.com/drugs/DB16355
    ApprovedInvestigational

    found to reduce the risk of death or hospitalization in high-risk adults with COVID-19 in the outpatient setting. … [L34440] Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 on May 26, 2021, based on interim results from a clinical trial, where sotrovimab was

  4. Drug

    Caplacizumab

    go.drugbank.com/drugs/DB06081
    ApprovedInvestigational

    Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. … Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression

    Products: Cablivi 10 mg/1 mL Enjeksiyonluk Çözelti Hazırlamak İçin Toz ve Çözücü, 1 ADET, Cablivi 10 mg/1 mL Enjeksiyonluk Çözelti Hazırlamak İçin Toz ve Çözücü, 7 ADET
  5. Drug

    AstraZeneca COVID-19 Vaccine

    go.drugbank.com/drugs/DB15656
    ApprovedInvestigational

    of October 2021. … The AstraZeneca COVID-19 Vaccine (previously known as ChAdOx1 nCoV-19 or AZD1222) is one of several vaccines developed in 2020 for the prevention of COVID-19 caused by SARS-CoV-2.

  6. Drug

    Vusolimogene oderparepvec

    go.drugbank.com/drugs/DB23008
    ApprovedInvestigational

    on a PD-1-blocking antibody-based regimen. … [L64061] It is administered by direct injection into superficial, deep, or visceral tumors.

  7. Drug

    Triazolam

    go.drugbank.com/drugs/DB00897
    ApprovedInvestigational

    Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances. … Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S.

    Products: TRIAZOLAM EG, Halcion 0,25 mg - Tabletten
  8. Drug

    Famtozinameran

    go.drugbank.com/drugs/DB17088
    ApprovedInvestigational

    The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. … [L43917] As of November 2022, it is the primary circulating variant of concern according to the World Health Organization.

  9. Drug

    CX-052075

    go.drugbank.com/drugs/DB31655
    Approved

    the SARS-CoV-2 spike protein, allowing for a more targeted immune response and the use of a significantly smaller amount of mRNA per dose. … CX-052075 is a nucleoside-modified messenger RNA (mRNA) encoding the N-terminal domain (NTD) and receptor-binding domain (RBD) of the spike glycoprotein of the SARS-CoV-2 Omicron variant sublineage LP.8.1

  10. Drug

    Hyaluronidase

    go.drugbank.com/drugs/DB14740
    ApprovedInvestigational

    [L13338] The action of hyaluronidase was first described in 1936, and named in 1939. … [A199047] Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338]